DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction

Xiuli Zhang, Ying Cheng, Yao Lu, Nanhui Xu, Zhi Guo, Meizhu Wu, Guosheng Lin, Mengying Yao, Yanyan Yang, Yao Lin, Jun Peng, Aling ShenClinical 2025 · DOI

TL;DR

This study reveals Death-associated protein kinase 1 (DAPK1) as a novel regulator of hypertension (HTN). By inhibiting DAPK1, researchers successfully lowered blood pressure and reduced vascular damage in animal models, suggesting DAPK1 as a promising therapeutic target for HTN.

What Problem Does This Paper Address?

Hypertension (HTN) remains a major global health challenge, affecting nearly a third of adults worldwide and significantly increasing the risk of cardiovascular disease, stroke, and kidney disease. Despite advancements in treatment, blood pressure control is often suboptimal, indicating that current therapies may not address all underlying mechanisms. The complex pathology of HTN involves vascular dysfunction, specifically increased vascular contractility. While the renin-angiotensin-aldosterone system (RAAS) and angiotensin II (Ang II) are known contributors to vasoconstriction and HTN, the precise molecular players involved in regulating this process are not fully understood. This paper aims to explore the largely uninvestigated role of Death-associated protein kinase 1 (DAPK1) in HTN pathogenesis, hypothesizing its involvement in vascular contractility.

Methods

The researchers employed a multi-pronged approach using both rat and mouse models of hypertension.

  • Genetic Manipulation:
    • Knockdown: Adeno-associated virus (AAV) vectors carrying short hairpin RNA (shRNA) targeting DAPK1 were used to reduce DAPK1 expression in spontaneously hypertensive rats (SHRs) and Wistar-Kyoto rats.
  • Knockout: DAPK1 knockout mice were generated to study the effects of complete DAPK1 deficiency.
  • Pharmacological Inhibition: A selective DAPK1 inhibitor, TC-DAPK6, was administered to mice.
  • Hypertension Induction: Angiotensin II (Ang II) infusion was used to induce hypertension in wild-type and DAPK1 knockout mice.
  • Physiological Measurements:
    • Blood Pressure (BP): Non-invasive tail-cuff measurements were used to assess systolic, diastolic, and mean arterial pressure.
  • Vascular Function: Pulse wave velocity (PWV) and abdominal aorta (AA) thickness were measured using ultrasound. Ex vivo isometric contraction of AA rings was performed to assess vascular reactivity.
  • Histopathology: Hematoxylin and eosin (H&E) staining was used to examine tissue damage in the aorta, heart, and kidneys.
  • Molecular Analysis:
    • Immunohistochemistry (IHC): Used to assess the expression of proteins like proliferating cell nuclear antigen (PCNA), DAPK1, and phosphorylated myosin light chain (p-MLC).
  • RNA Sequencing (RNA-seq): Performed on AA tissues to identify differentially expressed transcripts and enriched pathways related to HTN.
  • Western Blotting: Used to quantify protein levels, particularly phosphorylated forms of DAPK1 and MLC.
  • Immunofluorescence: Employed to visualize F-actin in vascular smooth muscle cells (VSMCs).
  • Intracellular Calcium Measurement: Real-time confocal microscopy was used to assess intracellular calcium levels in VSMCs.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • DAPK1 as a Vasoconstrictor Regulator: The study strongly suggests that DAPK1 plays a pro-vasoconstrictive role, contributing to elevated blood pressure in hypertension.
  • MLC Phosphorylation as the Mechanism: The core mechanistic insight is that DAPK1 promotes the phosphorylation of myosin light chain (MLC) at serine 19. This phosphorylation is a critical step in initiating and maintaining vascular smooth muscle contraction.
  • Ang II-DAPK1-MLC Axis: Angiotensin II (Ang II) stimulation appears to activate DAPK1, which in turn phosphorylates MLC, leading to increased vasoconstriction and hypertension.
  • Therapeutic Potential of DAPK1 Inhibition: Blocking DAPK1 activity, either genetically or pharmacologically, effectively reverses Ang II-induced hypertension and reduces damage to vital organs. This highlights DAPK1 as a promising drug target.
  • Dual Benefit of DAPK1 Inhibition: Targeting DAPK1 not only lowers blood pressure but also mitigates end-organ damage, offering a potential dual therapeutic benefit.

Key Results

  • DAPK1 Knockdown/Inhibition in Rats: In spontaneously hypertensive rats (SHRs), DAPK1 knockdown significantly reduced systolic, diastolic, and mean arterial blood pressure. It also decreased pulse wave velocity and aortic wall thickness, and attenuated cardiac and renal tissue damage.
  • DAPK1 Knockout in Mice: DAPK1 knockout mice showed significantly attenuated Ang II-induced hypertension, with no increase in blood pressure, pulse wave velocity, or aortic wall thickness compared to wild-type mice receiving Ang II. Organ damage was also reduced in knockout mice.
  • DAPK1 Inhibitor Efficacy: Treatment with the DAPK1 inhibitor TC-DAPK6 reversed Ang II-induced hypertension and vascular damage in mice, similar to the effects observed with DAPK1 knockout.
  • Mechanistic Evidence:
    • Ang II stimulation increased intracellular calcium in VSMCs, which was linked to DAPK1 activation (increased p-DAPK1/DAPK1 ratio).
  • DAPK1 inhibition (TC-DAPK6) significantly reduced the phosphorylation of MLC at serine 19 in both animal models and in vitro in VSMCs.
  • Ex vivo studies showed that DAPK1 knockout reduced Ang II-induced contraction of aortic rings.

Limitations and Future Work

  • Animal Models: While the study used established animal models of hypertension, further validation in other models (e.g., two-kidneys-one-clip, deoxycorticosterone acetate, salt-sensitive models) is suggested to confirm the broad applicability of these findings.
  • Vascular Resistance Studies: The authors recommend further studies to assess DAPK1's effect on resistance index, pulsatility index, vasoconstriction, and vasodilation in mesenteric arteries and small-sized arteries.
  • Broader Signaling Pathways: While the study highlights the Ca2+/DAPK1/p-MLC axis, further research is needed to explore other implicated signaling pathways and how DAPK1 interacts with them.
  • Clinical Translation: The findings provide a strong foundation for developing DAPK1 inhibitors as therapeutic agents for HTN, but clinical trials would be the next crucial step.
  • DAPK1 Expression in Human HTN: The paper notes that DAPK1 expression was not affected in the AA of Ang II-infused mice, but p-DAPK (S308) was down-regulated. Further investigation into DAPK1 and its phosphorylated forms in human hypertensive vasculature would be valuable.

Summary updated

Abstract

Death-associated protein kinase 1 (DAPK1) is a tumor suppressor gene involved in apoptosis, autophagy, and tumor progression. However, its role in hypertension (HTN) remains largely unexplored and lacks systematic evaluation. We administered adeno-associated virus (AAV) harboring short hairpin RNA targeting DAPK1 or control short hairpin RNA to male spontaneously hypertensive rats (SHRs) and Wistar-Kyoto rats. Additionally, wildtype and DAPK1 knockout mice were infused with angiotensin II (Ang II) or saline for four weeks. Male C57BL/6 mice underwent a four-week Ang II infusion and were treated with TC-DAPK6, a selective DAPK1 inhibitor. We examined the abdominal aortas (AAs) of mice and rats for pathological changes, measured blood pressure (BP) and pulse wave velocity using noninvasive BP methods, ultrasound, and hematoxylin and eosin staining. The role of DAPK1 in early HTN was further assessed through immunofluorescence, ex vivo isometric constriction of the AA, RNA sequencing, Western blot, and immunohistochemistry. Our study demonstrated that the targeted inhibition of DAPK1 with AAV significantly ameliorated HTN in SHRs and reduced damage to the AAs and target organs, including the heart and kidneys. Meanwhile, DAPK1 knockout or inhibition in mice significantly ameliorates Ang II-induced HTN in mice, as well as reducing damage to the AAs and target organs, including the heart and kidneys. Mechanistically, DAPK1 inhibition prevents myosin light chain (MLC) phosphorylation at serine 19, reducing vasoconstriction and protecting against HTN. In conclusion, DAPK1 is involved in HTN pathogenesis by regulating the MLC pathway to mediate vascular constriction, highlighting potential as a therapeutic target for HTN.
BibTeX
@inproceedings{zhang2025dapk,
  author = {Xiuli Zhang and Ying Cheng and Yao Lu and Nanhui Xu and Zhi Guo and Meizhu Wu and Guosheng Lin and Mengying Yao and Yanyan Yang and Yao Lin and Jun Peng and Aling Shen},
  title = {{DAPK1 acts as a positive regulator of hypertension via induction of vasoconstriction}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1042/cs20255840},
}
Figure